Health At Sanofi, a flu expert sees potential for improved vaccines @HelenBranswell Tags businessinfectious diseaseSTAT+ Sanofi is one of the world’s leaders in influenza vaccine production, through its vaccine arm Sanofi Pasteur.And if anyone at Sanofi knows vaccines, it’s Dr. Gary Nabel, the company’s chief scientific officer, who happens to be a former head of the National Institutes of Health’s Vaccine Research Center. Helen Branswell What’s included? Dr. Gary Nabel, Sanofi’s chief scientific officer and a former head of the NIH’s Vaccine Research Center. Hyacinth Empinado/STAT STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Log In | Learn More Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints By Helen Branswell July 31, 2018 Reprints Senior Writer, Infectious Disease Helen covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. GET STARTED What is it?